SeqOne Platform

Laboratory genomic analysis platform for oncology, inherited and infectious disease, with the DiagAI variant-prioritisation model; IVDR Class C certified by GMED, according to the company.

seqone.com

At a glance

Type: SaaS
Platforms: Web
Who it’s for: Clinicians, health systems and researchers
Where it’s available: France, United Kingdom
Sources cited: 5
In the library since: 24 September 2026

Regulatory status: IVDR Class C certification from the notified body GMED, as stated by the company (14 November 2024); the certificate was not read.As recorded from the regulator or the company, with its attribution.

What it does

SeqOne describes its platform as AI-powered bioinformatics that turns genomic data into actionable insights, with applications in oncology, inherited diseases and infectious diseases and the DiagAI variant-prioritisation model. Its Spring 2026 release lists a large variant viewer, a rebuilt variant knowledge base, new whole-genome callers and a public API, which the company says are all IVDR-certified.

Independent evidence

Established from a source other than the company.

A peer-reviewed study of DiagAI, published on 11 July 2026 in Current Issues in Molecular Biology, reports that on 196 diagnosed exomes from adults with nephropathy of unknown origin the DiagAI shortlist contained the causal variant in 94.9% of cases with phenotype terms and 90.8% without. The study is company-authored and evaluates one specialty.